PhD Program in Health Sciences, UCAM - Universidad Católica San Antonio de Murcia, Murcia, Spain.
Department of Pathology & Laboratory Medicine, Cardiovascular Research Institute, Health Science Division, Loyola University Chicago, Maywood, Illinois, USA.
Clin Appl Thromb Hemost. 2024 Jan-Dec;30:10760296241261076. doi: 10.1177/10760296241261076.
Pulmonary embolism (PE) is a heterogenous condition with variable clinical presentations. Thrombin generation potential (TGP) and biomarkers, and blood cellular indices can reflect the underlying pathophysiology and risk stratification of PE. This case-control study analyzed TGP in 209 PE patients from Loyola University, Pulmonary Embolism Response Team program compared to normal human plasma (NHP) controls. The present study evaluates TGP and biomarkers, and cellular indices in relation to PE severity, according to the European Society of Cardiology (ESC) guidelines. Statistical analysis including median with interquartile range (IQR), 2-tailed Wilcoxon Mann-Whitney test, Chi-square test, and Spearman Correlational analysis were performed. There were 209 patients with PE, with an almost equal distribution between sex, and a median age of 63 years. Significant downregulation in peak thrombin and endogenous thrombin potential (ETP), as well as upregulation in lag time, were observed in PE patients versus controls. Biomarker analysis revealed pronounced elevations, with D-dimer demonstrating the most significant increase. Blood cellular indices also rose in PE patients, correlating with disease severity. PE severity was associated with higher TGP and biomarker levels. Mortality rates differed significantly across risk categories and were highest in patients with elevated cellular indices. TGP and biomarkers are intricately linked to PE severity and can aid in risk stratification. Elevated cellular indices are associated with increased mortality, highlighting their potential as prognostic markers. These findings could enhance the precision of PE management strategies.
肺栓塞(PE)是一种临床表现多样的异质性疾病。凝血酶生成潜能(TGP)和生物标志物以及血液细胞指数可以反映 PE 的潜在病理生理学和风险分层。这项病例对照研究分析了来自洛约拉大学的 209 名 PE 患者的 TGP,这些患者来自肺栓塞反应团队计划,并与正常人类血浆(NHP)对照进行了比较。本研究根据欧洲心脏病学会(ESC)指南评估了 TGP 和生物标志物以及与 PE 严重程度相关的细胞指数。进行了包括中位数和四分位距(IQR)、双侧 Wilcoxon 曼-惠特尼检验、卡方检验和斯皮尔曼相关分析在内的统计分析。有 209 名 PE 患者,男女分布几乎相等,中位年龄为 63 岁。与对照组相比,PE 患者的峰值凝血酶和内源性凝血酶潜能(ETP)显著下调,而滞后时间上调。生物标志物分析显示明显升高,其中 D-二聚体升高最显著。PE 患者的血液细胞指数也升高,与疾病严重程度相关。PE 严重程度与更高的 TGP 和生物标志物水平相关。风险类别之间的死亡率差异显著,细胞指数升高的患者死亡率最高。TGP 和生物标志物与 PE 严重程度密切相关,可用于风险分层。升高的细胞指数与死亡率增加相关,提示其作为预后标志物的潜力。这些发现可以提高 PE 管理策略的准确性。